Built by people
who've done it before.

25+ years driving pharmaceutical growth across European markets. Former CEO of Flynn Pharma and Interim Commercial Director at Rosemont Pharmaceuticals. Previously VP & GM Northern Europe and UK & Ireland GM at Sobi, UK Country Lead at GenSight Biologics, and Director of Oncology at Merck Serono. Specialist in rare diseases, oncology, and specialty therapeutics.

40+ years transforming complex business scenarios. Founder & CFO of Alverium Health (contract biotech). Previously Finance Director and Founding Partner at FleetEurope PLC, Partner at TISE Associates, and Senior Group Manager at Unilever. Deep expertise in business strategy, M&A, and financial management for life sciences.

20+ years in personal care and specialty chemicals product development. Previously Global Head of Hair Care Technology at Lonza, and Technical & Operations Director at Perachem. Holds numerous patents and peer-reviewed publications. Expert in R&D, intellectual property, regulatory matters and commercialising disruptive technologies.

18+ years guiding early-stage biotechs from concept to exit. Involved in 10+ transitions including Synageva, Kite, GW Pharmaceuticals, Shire, and Intercept. Partners with CEOs and investors on strategic resourcing and executive team building across US, European, and emerging markets.

30+ years at board level in FTSE 50 companies. Senior lawyer in the core deal team for the 2001 GlaxoWellcome and SmithKline Beecham merger as well as the creation of global joint ventures between GSK and Novartis/Pfizer in 2014 and 2018 respectively. SVP, General Counsel and Chief Compliance Officer at GSK Consumer Healthcare (now Haleon, a separate FTSE 50 company) and Chief Legal and Corporate Affairs Officer at Imperial Brands. Expert in legal and compliance frameworks for regulated businesses.

30+ years in global pharmaceutical business development and M&A. Former Royal Navy officer with senior roles at Aventis, Serono, Takeda, Quintiles, Epirus, and mAbxience. Led major transactions including Nycomed and Valeant acquisitions. Independent consultant for biotech startups and academic spin-outs globally.

20+ years developing and commercialising precision medicine and diagnostics platforms. Senior Director at Endpoint Health, previously led product management at Roche, Life Technologies, and Beckman Coulter. Launched 10+ successful products globally. Founder of Scriptyx, a healthcare technology and business development enterprise. Expert in strategic marketing and disruptive health technology commercialisation.